This inventor holds 5 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Cytovac A/s, Dandrit Biotech A/s, Dandrit Diotech A/s. Active years: 2010-2018.
Location History:
- Copenhagen, DK (2010 - 2017)
- Copenhagen, RU (2018)
Company Filing History:
2 out of 2 
2 out of 2 
1 out of 1 Years Active: 2010-2018
Title: Alexei Kirkin: Innovator in Cancer Immunotherapy
Introduction
Alexei Kirkin is a prominent inventor based in Copenhagen, Denmark. He has made significant contributions to the field of cancer immunotherapy, holding a total of 5 patents. His innovative work focuses on developing novel approaches to enhance the immune response against tumors.
Latest Patents
One of Kirkin's latest patents is an anti-tumor vaccine derived from normal cells. This composition is designed to induce an immune response in mammals by utilizing lymphoid cells with chemically induced expression of tumor antigens. The tumor antigens are typically cancer/testis antigens, which can be induced through DNA demethylation. This vaccine aims to provide a broad immune response against various tumors, making it a promising candidate for both prophylactic and therapeutic applications. Another notable patent involves a method for generating dendritic cells at temperatures below 37°C during the development of progenitor cells. This innovative approach has potential implications for enhancing the efficacy of dendritic cell-based therapies.
Career Highlights
Throughout his career, Kirkin has worked with several notable companies, including Dandrit Biotech A/S and Cytovac A/S. His expertise in immunology and cell therapy has positioned him as a key figure in the development of cutting-edge cancer treatments.
Collaborations
Kirkin has collaborated with esteemed colleagues such as Karine Djandjougazian and Jesper Zeuthen. These partnerships have further enriched his research and contributed to advancements in the field of cancer immunotherapy.
Conclusion
Alexei Kirkin's innovative work in cancer immunotherapy exemplifies the potential of harnessing the immune system to combat tumors. His contributions through patents and collaborations continue to pave the way for new therapeutic strategies in oncology.